Insmed Incorporated (0JAV.L)
USD 71.54
(-1.38%)
USD 71.54
(-1.38%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 721.62 Million USD | 595.01% |
| 2022 | 103.82 Million USD | 199.34% |
| 2021 | -104.51 Million USD | 18.29% |
| 2020 | -127.91 Million USD | -41.51% |
| 2019 | -90.39 Million USD | 49.36% |
| 2018 | -178.51 Million USD | 45.17% |
| 2017 | -325.59 Million USD | -202.04% |
| 2016 | -107.8 Million USD | 58.17% |
| 2015 | -257.73 Million USD | -91.81% |
| 2014 | -134.37 Million USD | -42.63% |
| 2013 | -94.2 Million USD | -31.96% |
| 2012 | -71.39 Million USD | -423.22% |
| 2011 | -13.64 Million USD | -28.98% |
| 2010 | -10.57 Million USD | 15.58% |
| 2009 | -12.53 Million USD | -29044.19% |
| 2008 | -43 Thousand USD | 99.67% |
| 2007 | -13.1 Million USD | 37.45% |
| 2006 | -20.95 Million USD | -68.99% |
| 2005 | -12.39 Million USD | -34.44% |
| 2004 | -9.22 Million USD | 68.77% |
| 2003 | -29.52 Million USD | -8.01% |
| 2002 | -27.33 Million USD | 46.66% |
| 2001 | -51.25 Million USD | 28.45% |
| 2000 | -71.62 Million USD | -22502.64% |
| 1999 | -316.9 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 132.57 Million USD | -82.89% |
| 2024 Q1 | 774.96 Million USD | 7.39% |
| 2024 Q3 | 538.41 Million USD | 306.12% |
| 2023 FY | 721.62 Million USD | 595.01% |
| 2023 Q3 | 710.08 Million USD | 23.54% |
| 2023 Q2 | 574.76 Million USD | 166.33% |
| 2023 Q1 | 215.8 Million USD | 107.85% |
| 2023 Q4 | 721.62 Million USD | 1.62% |
| 2022 Q2 | 414.48 Million USD | 29.29% |
| 2022 Q4 | 103.82 Million USD | -74.99% |
| 2022 Q1 | 320.58 Million USD | 406.74% |
| 2022 FY | 103.82 Million USD | 199.34% |
| 2022 Q3 | 415.14 Million USD | 0.16% |
| 2021 Q1 | -2.15 Million USD | 98.32% |
| 2021 Q3 | -245.35 Million USD | 26.76% |
| 2021 Q4 | -104.51 Million USD | 57.4% |
| 2021 Q2 | -334.97 Million USD | -15451.35% |
| 2021 FY | -104.51 Million USD | 18.29% |
| 2020 Q4 | -127.91 Million USD | 32.36% |
| 2020 FY | -127.91 Million USD | -41.51% |
| 2020 Q1 | -29.98 Million USD | 66.83% |
| 2020 Q2 | -243.15 Million USD | -711.05% |
| 2020 Q3 | -189.1 Million USD | 22.23% |
| 2019 FY | -90.39 Million USD | 49.36% |
| 2019 Q1 | -53.85 Million USD | 69.83% |
| 2019 Q2 | -232.41 Million USD | -331.6% |
| 2019 Q4 | -90.39 Million USD | 43.94% |
| 2019 Q3 | -161.22 Million USD | 30.63% |
| 2018 Q2 | -327.17 Million USD | 14.77% |
| 2018 FY | -178.51 Million USD | 45.17% |
| 2018 Q4 | -178.51 Million USD | 30.19% |
| 2018 Q1 | -383.87 Million USD | -17.9% |
| 2018 Q3 | -255.71 Million USD | 21.84% |
| 2017 Q4 | -325.59 Million USD | 13.24% |
| 2017 Q3 | -375.29 Million USD | -946.25% |
| 2017 Q2 | -35.87 Million USD | 49.37% |
| 2017 FY | -325.59 Million USD | -202.04% |
| 2017 Q1 | -70.84 Million USD | 34.28% |
| 2016 Q4 | -107.8 Million USD | 35.0% |
| 2016 FY | -107.8 Million USD | 58.17% |
| 2016 Q1 | -228.08 Million USD | 11.5% |
| 2016 Q2 | -198.28 Million USD | 13.07% |
| 2016 Q3 | -165.83 Million USD | 16.36% |
| 2015 Q4 | -257.73 Million USD | 9.79% |
| 2015 Q1 | -109.56 Million USD | 18.46% |
| 2015 FY | -257.73 Million USD | -91.81% |
| 2015 Q2 | -309.9 Million USD | -182.85% |
| 2015 Q3 | -285.71 Million USD | 7.81% |
| 2014 Q4 | -134.37 Million USD | 8.84% |
| 2014 Q3 | -147.4 Million USD | -134.38% |
| 2014 Q1 | -81.44 Million USD | 13.55% |
| 2014 FY | -134.37 Million USD | -42.63% |
| 2014 Q2 | -62.89 Million USD | 22.78% |
| 2013 FY | -94.2 Million USD | -31.96% |
| 2013 Q1 | -59.91 Million USD | 16.08% |
| 2013 Q2 | -54.94 Million USD | 8.3% |
| 2013 Q4 | -94.2 Million USD | 13.05% |
| 2013 Q3 | -108.35 Million USD | -97.21% |
| 2012 Q3 | -35.7 Million USD | -91.88% |
| 2012 Q2 | -18.6 Million USD | 11.16% |
| 2012 FY | -71.39 Million USD | -423.22% |
| 2012 Q1 | -20.94 Million USD | -53.5% |
| 2012 Q4 | -71.39 Million USD | -99.96% |
| 2011 Q4 | -13.64 Million USD | -31.85% |
| 2011 Q3 | -10.34 Million USD | -6.5% |
| 2011 Q2 | -9.71 Million USD | 55.75% |
| 2011 FY | -13.64 Million USD | -28.98% |
| 2011 Q1 | -21.95 Million USD | -107.55% |
| 2010 Q1 | -19.36 Million USD | -54.52% |
| 2010 FY | -10.57 Million USD | 15.58% |
| 2010 Q4 | -10.57 Million USD | -9.06% |
| 2010 Q3 | -9.7 Million USD | 14.28% |
| 2010 Q2 | -11.31 Million USD | 41.56% |
| 2009 Q3 | -26.44 Million USD | 26.2% |
| 2009 Q2 | -35.82 Million USD | 71.51% |
| 2009 Q1 | -125.76 Million USD | -292376.74% |
| 2009 FY | -12.53 Million USD | -29044.19% |
| 2009 Q4 | -12.53 Million USD | 52.6% |
| 2008 FY | -43 Thousand USD | 99.67% |
| 2008 Q1 | -8.94 Million USD | 31.71% |
| 2008 Q4 | -43 Thousand USD | 98.71% |
| 2008 Q3 | -3.32 Million USD | 50.19% |
| 2008 Q2 | -6.67 Million USD | 25.42% |
| 2007 Q4 | -13.1 Million USD | 15.57% |
| 2007 FY | -13.1 Million USD | 37.45% |
| 2007 Q1 | -8.8 Million USD | 57.99% |
| 2007 Q2 | -18.94 Million USD | -115.28% |
| 2007 Q3 | -15.52 Million USD | 18.09% |
| 2006 Q3 | -31.36 Million USD | 30.0% |
| 2006 Q4 | -20.95 Million USD | 33.2% |
| 2006 Q2 | -44.8 Million USD | 19.6% |
| 2006 Q1 | -55.73 Million USD | -349.53% |
| 2006 FY | -20.95 Million USD | -68.99% |
| 2005 Q2 | -8.64 Million USD | 49.59% |
| 2005 Q3 | 3.5 Million USD | 140.5% |
| 2005 FY | -12.39 Million USD | -34.44% |
| 2005 Q4 | -12.39 Million USD | -454.23% |
| 2005 Q1 | -17.14 Million USD | -85.86% |
| 2004 Q3 | -7.5 Million USD | 46.57% |
| 2004 Q1 | -24.9 Million USD | 15.64% |
| 2004 FY | -9.22 Million USD | 68.77% |
| 2004 Q4 | -9.22 Million USD | -22.81% |
| 2004 Q2 | -14.05 Million USD | 43.57% |
| 2003 Q2 | -22 Million USD | 12.37% |
| 2003 Q4 | -29.52 Million USD | 8.27% |
| 2003 Q3 | -32.18 Million USD | -46.26% |
| 2003 Q1 | -25.11 Million USD | 8.12% |
| 2003 FY | -29.52 Million USD | -8.01% |
| 2002 Q1 | -42.36 Million USD | 17.34% |
| 2002 Q2 | -36.26 Million USD | 14.4% |
| 2002 Q3 | -31.17 Million USD | 14.02% |
| 2002 FY | -27.33 Million USD | 46.66% |
| 2002 Q4 | -27.33 Million USD | 12.32% |
| 2001 Q4 | -51.25 Million USD | 10.62% |
| 2001 FY | -51.25 Million USD | 28.45% |
| 2001 Q1 | -72.12 Million USD | -0.69% |
| 2001 Q3 | -57.33 Million USD | 14.24% |
| 2001 Q2 | -66.86 Million USD | 7.29% |
| 2000 Q4 | -71.62 Million USD | -143.85% |
| 2000 Q3 | -29.37 Million USD | 16.41% |
| 2000 Q2 | -35.13 Million USD | -1243.75% |
| 2000 FY | -71.62 Million USD | -22502.64% |
| 2000 Q1 | -2.61 Million USD | 0.0% |
| 1999 FY | -316.9 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 800.935% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 2411.625% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -264.335% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -2163.196% |
| bluebird bio, Inc. | 108.57 Million USD | -564.653% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 8103.771% |
| Imunon, Inc. | -4.69 Million USD | 15455.992% |
| Editas Medicine, Inc. | -87.11 Million USD | 928.344% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 94.386% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 65.604% |
| Myriad Genetics, Inc. | 88.1 Million USD | -719.092% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -307.005% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 2252.355% |
| Verastem, Inc. | -37.27 Million USD | 2035.78% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 91.237% |
| Waters Corporation | 1.96 Billion USD | 63.191% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 97.311% |
| Biogen Inc. | 6.28 Billion USD | 88.524% |
| Nektar Therapeutics | 210.24 Million USD | -243.236% |
| Perrigo Company plc | 3.32 Billion USD | 78.278% |
| Dynavax Technologies Corporation | 106.63 Million USD | -576.72% |
| Illumina, Inc. | 1.21 Billion USD | 40.558% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -10256.087% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 733.623% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -397.408% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -9940.629% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -90.528% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 10263.662% |
| Evolus, Inc. | 63.7 Million USD | -1032.699% |
| Adicet Bio, Inc. | -142 Million USD | 608.154% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 2060.711% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 2762.804% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -57.319% |
| FibroGen, Inc. | 56.76 Million USD | -1171.196% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 36.976% |
| OPKO Health, Inc. | 230.68 Million USD | -212.819% |
| Homology Medicines, Inc. | 18.43 Million USD | -3813.977% |
| Geron Corporation | 14.76 Million USD | -4788.693% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 54.481% |
| Exelixis, Inc. | -73.05 Million USD | 1087.844% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 1430.028% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 577.818% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 747.762% |
| Zoetis Inc. | 4.76 Billion USD | 84.846% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 461.133% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 7265.326% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 107.545% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 5052.1% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 31.553% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 25.482% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 632.954% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 47.742% |
| Blueprint Medicines Corporation | 702.83 Million USD | -2.673% |
| TG Therapeutics, Inc. | 17.86 Million USD | -3939.973% |
| Incyte Corporation | -3.17 Billion USD | 122.728% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 5.769% |